Innovative strategies for early detection of cardiotoxicity: artificial intelligence and multi-modality collaborative...

Area of Science:

• Cardio-Oncology
• Drug Safety
• Regulatory Science

Background:

• Cancer therapeutics development is rapidly advancing, necessitating robust patient safety measures, particularly cardiovascular safety.
• Regulatory agencies like the FDA face resource constraints, highlighting the need for automated solutions and data standardization.
• Cardiovascular safety in oncology drug development requires enhanced oversight through collaboration and technological innovation.

Purpose of the Study:

• To outline public-private partnerships and collaborative oversight models for strengthening cardio-oncology safety.
• To propose a strategic forecasting and preparedness framework for managing cardiotoxicity risks.
• To leverage technology and interdisciplinary approaches for predictive modeling and monitoring.

Main Methods:

• Establishing public-private partnerships involving sponsors, regulators, health systems, payers, and patient groups.
• Implementing continuous surveillance, standardized cardiac endpoints, and transparent data sharing.
• Developing a framework incorporating AI-enabled signal detection, real-world evidence (RWE), and pre-specified label-update triggers.

Main Results:

• The proposed framework operationalizes continuous surveillance and data sharing for improved safety oversight.
• Integration of AI and RWE can enhance predictive modeling and risk-benefit assessment for cancer therapeutics.
• Modernized cardiotoxicity detection through policy and technology innovations is achievable.

Conclusions:

• Collaborative models and technological advancements are crucial for ensuring cardiovascular safety in cancer therapeutics.
• A proactive, data-driven approach is needed to modernize cardiotoxicity detection and protect patients.
• Policy and technology innovations can sustain the benefits of oncology care while managing drug-related cardiac risks.